Korro Bio Unveils Pipeline Advancements in RNA Editing for Genetic Medicines

Reuters01-16

<a href="https://laohu8.com/S/KRRO">Korro Bio</a> Unveils Pipeline Advancements in RNA Editing for Genetic Medicines

Korro Bio Inc. has provided an update on its pipeline of RNA editing-based therapeutic candidates targeting rare and prevalent diseases. The company highlighted the progress of its lead asset, KRRO-121, aimed at treating hyperammonemia, with an update expected on January 27, 2026. Additional programs include efforts to repair pathogenic variants in Alpha-1 Antitrypsin Deficiency (AATD) and to develop allosteric activators for longevity, all utilizing GalNAc-based delivery for liver targeting. The presentation also outlined anticipated milestones for 2026 and described the company's emphasis on leveraging ADAR biology, machine learning, and advanced chemistry to drive drug discovery and development. Korro Bio reported a cash position of $102.5 million as of September 30, 2025, projecting a runway into the second half of 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603384959?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 03:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603384959","market":"nz","top_or_hot":-1,"title":"Korro Bio Unveils Pipeline Advancements in RNA Editing for Genetic Medicines","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> Unveils Pipeline Advancements in RNA Editing for Genetic Medicines\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Korro Bio Inc. has provided an update on its pipeline of RNA editing-based therapeutic candidates targeting rare and prevalent diseases. The company highlighted the progress of its lead asset, KRRO-121, aimed at treating hyperammonemia, with an update expected on January 27, 2026. Additional programs include efforts to repair pathogenic variants in Alpha-1 Antitrypsin Deficiency (AATD) and to develop allosteric activators for longevity, all utilizing GalNAc-based delivery for liver targeting. The presentation also outlined anticipated milestones for 2026 and described the company's emphasis on leveraging ADAR biology, machine learning, and advanced chemistry to drive drug discovery and development. Korro Bio reported a cash position of $102.5 million as of September 30, 2025, projecting a runway into the second half of 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Korro Bio Unveils Pipeline Advancements in RNA Editing for Genetic Medicines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKorro Bio Unveils Pipeline Advancements in RNA Editing for Genetic Medicines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-16 03:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> Unveils Pipeline Advancements in RNA Editing for Genetic Medicines\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Korro Bio Inc. has provided an update on its pipeline of RNA editing-based therapeutic candidates targeting rare and prevalent diseases. The company highlighted the progress of its lead asset, KRRO-121, aimed at treating hyperammonemia, with an update expected on January 27, 2026. Additional programs include efforts to repair pathogenic variants in Alpha-1 Antitrypsin Deficiency (AATD) and to develop allosteric activators for longevity, all utilizing GalNAc-based delivery for liver targeting. The presentation also outlined anticipated milestones for 2026 and described the company's emphasis on leveraging ADAR biology, machine learning, and advanced chemistry to drive drug discovery and development. Korro Bio reported a cash position of $102.5 million as of September 30, 2025, projecting a runway into the second half of 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRRO","symbol_name":"Korro Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL1kn4Xv:1","article_id":"2603384959","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603384959","pubTimestamp":1768505253,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Korro Bio Inc. has provided an update on its pipeline of RNA editing-based therapeutic candidates targeting rare and prevalent diseases. The company highlighted the progress of its lead asset, KRRO-121, aimed at treating hyperammonemia, with an update expected on January 27, 2026. Additional programs include efforts to repair pathogenic variants in Alpha-1 Antitrypsin Deficiency  and to develop allosteric activators for longevity, all utilizing GalNAc-based delivery for liver targeting. The presentation also outlined anticipated milestones for 2026 and described the company's emphasis on leveraging ADAR biology, machine learning, and advanced chemistry to drive drug discovery and development. Korro Bio reported a cash position of $102.5 million as of September 30, 2025, projecting a runway into the second half of 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRRO":"Korro Bio, Inc.","BK4139":"生物科技"},"translate_title":"Korro Bio公布基因药物RNA编辑的管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRRO":0.9},"content_text":"Korro Bio Unveils Pipeline Advancements in RNA Editing for Genetic Medicines\n    \n\n        Korro Bio Inc. has provided an update on its pipeline of RNA editing-based therapeutic candidates targeting rare and prevalent diseases. The company highlighted the progress of its lead asset, KRRO-121, aimed at treating hyperammonemia, with an update expected on January 27, 2026. Additional programs include efforts to repair pathogenic variants in Alpha-1 Antitrypsin Deficiency (AATD) and to develop allosteric activators for longevity, all utilizing GalNAc-based delivery for liver targeting. The presentation also outlined anticipated milestones for 2026 and described the company's emphasis on leveraging ADAR biology, machine learning, and advanced chemistry to drive drug discovery and development. Korro Bio reported a cash position of $102.5 million as of September 30, 2025, projecting a runway into the second half of 2027. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603384959","isCrawlerRequest":true}